SAFETELMI-HFILM-COATED

Hypertension

Oral Hypertension Adult: Initially, 40 mg once daily. Max: 80 mg/day.  Renal impairment: Severe impairment/ Haemodialysis: Initial dose 20 mg/day. Hepatic impairment: Mild to moderate: Max 40 mg/day. Severe: Contra-indicated

May be taken with or without food.

Hypotension, dizziness, tachycardia or bradycardia. Supportive treatment to be instituted. Not removed by haemodialysis.

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes. Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.

Concurrent use increases digoxin concentration; increases risk of lithium toxicity; increases risk of hyperkalaemia with potassium sparing diuretics, heparin.

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. in 2nd & 3rd trimesters.         Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Oral: Store at 15-30°C.

Telmisartan is a nonpeptide AT 1  angiotensin II receptor antagonist. Exerts antihypertensive activity by preventing angiotensin II from binding to AT 1  receptors thus inhibiting the vasoconstriction and aldosterone-secreting effects of angiotensin II. Absorption: Rapidly absorbed. Dose dependent bioavailability 42% (after 40 mg dose); 58% (after 160-mg dose). Peak plasma concentrations: 0.5-1hr. Distribution: Protien binding: 99%. Metabolism: Undergoes conjugation with glucuronic acid to form inactive metabolites. Excretion: Excreted almost entirely as unchanged drug in faeces via bile. <1% excreted via urine. Terminal elimination half-life: 24 hr.

Angiotensin II Antagonists

C09CA07 - telmisartan; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.

*telmisartan information: Note that there are some more drugs interacting with telmisartan telmisartan further details are available in official CIMS India telmisartan telmisartan brands available in India Always prescribe with Generic Name : telmisartan,

Food slightly reduces the bioavailability.